Harmony Biosciences highlights best-in-class orexin-2 agonist, $3B revenue goal at Investor Day

Harmony Biosciences Holdings, Inc.

BP1.15205 orexin-2 agonist shows highest potency vs. all publicly disclosed competitors, potential best-in-class.
Pitolisant in IH: mean ESS improvement ~9 points beyond 1 year; majority achieve normal wakefulness; sNDA on track Q4 2024.
Pitolisant-HD safety data up to 5x highest WAKIX dose; target PDUFA 2028; market research anticipates high uptake.
Fragile X (ZYN-002): 40% median improvement in social avoidance (p=0.027) in methylated patients; Phase 3 topline mid-2025.
EPX-100 in Dravet syndrome shows favorable safety vs approved drugs; topline 2026; Phase 3 LGS starts 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.